<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Dev Immunol</journal-id><journal-title>Clinical and Developmental Immunology</journal-title><issn pub-type="ppub">1740-2522</issn><issn pub-type="epub">1740-2530</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16603440</article-id><article-id pub-id-type="pmc">2270744</article-id>
		<article-id pub-id-type="pii">S1740252206000023</article-id>
		<article-id pub-id-type="doi">10.1080/17402520600557867</article-id>
	<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Serum Islet Cell Autoantibodies During Interferon &#x003b1; Treatment in Patients With HCV-Genotype 4 Chronic Hepatitis </article-title></title-group><contrib-group>
		<contrib contrib-type="author"><name><surname>Badra</surname><given-names>Gamal</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib>
		<contrib contrib-type="author"><name><surname>Waked</surname><given-names>Imam</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib>
		<contrib contrib-type="author"><name><surname>Selmi</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib>
		<contrib contrib-type="author"><name><surname>Saleh</surname><given-names>Saleh M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib>
		<contrib contrib-type="author"><name><surname>El-Shaarawy</surname><given-names>Ahmed</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib>
		<contrib contrib-type="author"><name><surname>Lotfy</surname><given-names>Mahmoud</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib>
	</contrib-group>
		<aff id="aff1"><label>1</label>
			<addr-line>Department of Hepatology</addr-line>
			<addr-line>National Liver Institute</addr-line>
			<addr-line>Minufiya University</addr-line>
			<addr-line>Minufiya</addr-line>
			<country>Egypt</country>
		</aff>
		<aff id="aff2"><label>2</label>
			<addr-line>Division of Internal Medicine</addr-line>
			<addr-line>San Paolo School of Medicine</addr-line>
			<addr-line>University of Milan</addr-line>
			<addr-line>Milan</addr-line>
			<country>Italy</country>
		</aff>
		<aff id="aff3"><label>3</label>
			<addr-line>Division of Rheumatology, Allergy, and Clinical Immunology</addr-line>
			<addr-line>University of California</addr-line>
			<addr-line>Davis</addr-line>
			<addr-line>California</addr-line>
			<country>USA</country>
		</aff>
		<aff id="aff4"><label>4</label>
			<addr-line>Clinical Pathology Division</addr-line>
			<addr-line>National Liver Institute</addr-line>
			<addr-line>Minufiya University</addr-line>
			<addr-line>Minufiya</addr-line>
			<country>Egypt</country>
		</aff>
		<aff id="aff5"><label>5</label>
			<addr-line>Molecular and Cellular Biology Department</addr-line>
			<addr-line>Genetic Engineering and Biotechnology Research Institute</addr-line>
			<addr-line>Minufiya University</addr-line>
			<addr-line>Sadat City</addr-line>
			<addr-line>Minufiya</addr-line>
			<country>Egypt</country>
		</aff>
	<pub-date pub-type="ppub"><month>3</month><year>2006</year></pub-date><volume>13</volume><issue>1</issue><fpage>11</fpage><lpage>15</lpage><permissions><copyright-statement>Copyright &#x000a9; 2006 Hindawi Publishing Corporation.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Hindawi Publishing Corporation</copyright-holder><license license-type="open-access" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract>
		<p>Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide and HCV genotype 4 (HCV4) is predominant in African and Middle Eastern countries. It is well established that interferon-&#x003b1; (IFNa) treatment for HCV may trigger serum autoantibodies against pancreatic islet cells (ICA) in a subgroup of patients. Available data on the incidence of ICA during IFNa therapy for chronic HCV4 infection are not conclusive. We investigated the appearance of ICA in 40 na&#x000ef;ve Egyptian patients (38 males, 32 &#x000b1; 6 years) with histologically defined chronic HCV4 infection undergoing IFNa treatment at a dose of 9-million U/week for 24 weeks. Serum samples were collected at baseline and following IFNa therapy and ICA were detected using indirect immunofluorescence. Baseline evaluation indicated that 2/40 (5%) patients had detectable serum ICA. After the completion of the treatment scheme, 12/38 (32%) previously ICA negative patients became ICA positive; however, no patient developed impaired glucose tolerance (IGT) or diabetes during follow-up. In conclusion, we submit that IFNa treatment for chronic hepatitis C (CHC) may induce serum ICA in one-third of Egyptian patients with HCV4. These autoantibodies, however, do not lead to alterations in glucose metabolism.</p>
	</abstract></article-meta></front></article>


